Lorca

Psoriatic arthritis PsA is a type of arthritis that causes joint swelling and stiffness, often occurring in people with the skin condition psoriasis. This study aims to understand how long patients continue treatment and how effective risankizumab RZB is compared to other advanced treatments for PsA in everyday clinical settings. The study will take place outside the United States across about 15 countries, involving between 900 and 1200 adult participants. Participants will receive either risankizumab or other biologic disease-modifying antirheumatic drugs bDMARDs as prescribed by their doctors following local guidelines. Treatments will be given as part of regular medical care without additional interventions from the study. Participants will be followed and observed for 24 months during their routine clinical visits. During the study, participants will attend their usual medical appointments where doctors will monitor their treatment persistence and response. The main outcome measured is how many participants continue their prescribed treatment up to 24 months. There is no expected extra burden or additional procedures for participants beyond their standard care.

The registry focuses on patients with venous thromboembolism VTE, including those often excluded from typical clinical trials such as pregnant women, elderly patients, and those with serious health conditions. It aims to improve medical knowledge and patient care by collecting detailed data on these patients clinical status and treatment outcomes. The project also seeks to develop predictive scores to identify patients at higher risk of complications from thromboembolic disease. This observational registry collects extensive information on patients diagnosed with VTE, including details on coexisting conditions, antithrombotic treatment type, dose, and duration, as well as outcomes during the first three months of therapy. It captures data on VTE recurrences, bleeding complications, and deaths, providing insights into real-world treatment and patient management. Participants provide informed consent and are followed for at least three months to monitor clinical outcomes. The registry supports physicians by giving access to data on patients with similar profiles to help manage complex cases. The main outcomes measured include VTE events and complications over a three-year period, supporting ongoing improvements in patient care and risk assessment.

Researchers are evaluating the effectiveness and safety of long-acting Cabotegravir plus Rilpivirine treatment in people living with HIV-1 who are aged 60 years or older. This study aims to compare the treatment results in this older population to those seen in younger patients. It also explores possible improvements in metabolic and liver health, as well as considers psychosocial factors such as stigma and psychological disorders that may affect older patients living with HIV. Participants will receive Cabotegravir 600 mg and Rilpivirine 900 mg injections into the muscle every two months after an initial induction phase with doses at months 1 and 2. The study focuses on patients who are stable on oral antiretroviral therapy ART and evaluates the switch to the long-acting injectable regimen over a 24-month period. During the study, participants will be regularly monitored for viral load levels, immune response, and any confirmed virologic failures. The research team will also track safety events related to the treatment. The primary outcome measured is the number of patients maintaining plasma HIV-1 RNA levels at or below 50 copiesmL after switching treatments at 12 months, with additional assessments conducted at 6, 12, and 24 months to monitor ongoing viral control and safety.